Table 4.

Effect size, its 95% CI, and % weight calculations for each selected study of CSF Aβ ₄₂ in Alzheimer's disease and dementia due to other causes.

S. no.	Author's name and year	Country where the studies were conducted	Aβ42 level (pg/mL) (AD and control)						Effect size (pg/mL)		95% CI	Weight	Aβ 42 level (pg/mL) (DOC and control)						Effect size (pg/mL)		95% CI	Weight
			Diseased			Control							Diseased			Control
			N	Md*	SD	N	Mc**	SD	RMD+	SE			N	Md*	SD	N	Mc**	SD	RMD+	SE
1	Galasko et al. (1998) [17]	USA	82	833	379	60	1485	473	−652.000	74.031	−797.10–−506.90	0.012	74	1129	464	60	1485	473	−356.000	81.475	−515.69–−196.31	0.011
2	Kanai et al. (1998) [19]	Japan	32	109.9	73.2	41	242	180	−132.100	30.947	−192.75–−71.45	0.069	33	209	180	41	242	180	−33.000	42.096	−115.51–−49.51	0.041
3	Andreasen et al. (2001) [7]	Sweden	105	523	180	18	897	242	−374.000	59.684	−490.98–−257.02	0.019	23	704	321	18	897	242	−193.000	87.941	−365.36–−20.64	0.009
4	Sjögren et al. (2002) [20]	Sweden	19	411	99	17	853	161	−442.000	45.173	−530.54–−353.46	0.033	15	680	96	17	853	161	−173.000	46.251	−263.65–−82.35	0.034
5	Grossman et al. (2005) [21]	USA	17	54	15.1	13	95.2	29.7	−41.200	9.015	−58.87–−23.53	0.819	13	44	14.1	13	95.2	29.7	−51.200	9.118	−69.07–−33.33	0.876
6	de Jong et al. (2006) [22]	The Netherlands	61	419	128	30	869	207	−450.000	41.193	−530.74–−369.26	0.039	25	655	220	30	869	207	−214.000	58.003	−327.68–−100.327	0.022
7	Bibl et al. (2007) [23]	Germany	15	310	90	15	810	320	−500.000	85.829	−668.22–−331.78	0.009	15	480	220	15	810	320	−330.000	100.266	−526.52–−133.48	0.007

*Mean in diseased group, **Mean in control group and raw mean difference.